Andrea S. Blevins Primeau, PhD, MBA

More than half of patients responded, and responses deepened over time.

There was an improvement in second progression-free survival, but not overall survival, with niraparib.

Rucaparib prolonged progression-free survival.

There was no benefit with atezolizumab, regardless of PD-L1 status.

Results suggest universal health care could reduce racial disparities in survival.

Researchers observed a “sharp” decline in public interest.

The aim of the trial was to determine if adjuvant atezolizumab improved disease-free survival.

TAK-700 plus ADT improved responses and progression-free survival compared with bicalutamide plus ADT.

The frequency of targetable alterations was roughly 22% in patients of African ancestry and those of European ancestry.

Although the standard of care for Ph+ ALL results in a 5-year overall survival of up to 50%, relapse is common and are frequently driven by the T3151 mutation in BCR-ABL.